Compare ADMA Biologics Inc (ADMA) vs Marqeta Inc (MQ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Marqeta Inc — how do they compare? ADMA Biologics Inc trades at $9.18 (market cap $2.13B), while Marqeta Inc trades at $15.42 (market cap $1.77B). The key difference: ADMA Biologics Inc is the larger of the two by market cap. Which is the better fit depends on your goals.
| ADMA | MQ | |
|---|---|---|
Market Cap | $2.13B | $1.77B |
Sector | Health | Technology |
52-Week High | $20.38 | $27.32 |
52-Week Low | $7.60 | $15.04 |
Enterprise Value | $2.20B | $1.07B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Marqeta (MQ) trades at $15.93, down 8.63% on the day, with a bullish technical outlook and mixed fundamentals. The stock recently underwent a 4:1 reverse split effective July 1, 2026. Q1 2026 earnings beat expectations with EPS of $0.08 versus -$0.0136 forecast, though Q4 2025 missed. Revenue trends show recovery from 2024's $507M to $625M in 2025, with net income narrowing losses. Analyst consensus is a $19 price target with 32% buy ratings.
The outlook hinges on execution of European expansion and credit product growth, but high P/E of 420.88 reflects significant growth expectations. Risks include ongoing profitability challenges, competitive fintech pressure, and shareholder litigation. Institutional sentiment is cautiously optimistic given the price target upside, but the stock remains speculative until sustained profitability is achieved.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Marqeta Inc
Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
Read more on MQ →
